NCT02681302: A trial that was reported late by Hackensack Meridian Health
This trial has reported, although it was 3 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02681302 |
|---|---|
| Title | Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 7, 2016 |
| Completion date | May 10, 2024 |
| Required reporting date | May 10, 2025, midnight |
| Actual reporting date | May 13, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 3 |